AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01030965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once-daily
Study NCT01584921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin (Epoetin-beta, NeoRecormon®)
Description: 5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
Study NCT01584921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin (Epoetin-beta, NeoRecormon®)
Description: 30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding.
Study NCT01584921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
Study NCT00059371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: male circumcision
Study NCT00059371 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: male circumcision
Study NCT04978025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Silver
Description: Orally: colloidal silver 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon)~and By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.
Study NCT04978025 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.
Study NCT01124396 — intervention group
Intervention type: DRUG
Intervention: DSP-3025
Study NCT01124396 — intervention group
Intervention type: DRUG
Intervention: Placebo
Study NCT01417078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: single-dose; dosage in mg, based on patient body weight
Study NCT00098371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alvocidib
Study NCT03421860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with ephedrine
Description: measure cardiac output after giving a bolus of ephedrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Study NCT03421860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with phenylephrine
Description: measure cardiac output after giving a bolus of phenylephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Study NCT03421860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with ondansetron
Description: measure cardiac output after giving a bolus of ondansetron intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Study NCT03421860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cardiac output changes with nor-epinephrine
Description: measure cardiac output after giving a bolus of nor-epinephrine intervention: will receive complementary doses of ephedrine to maintain systolic blood pressure above 80 % of baseline
Study NCT03767192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: SPG stimulation and standard of care
Study NCT03767192 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham SPG stimulation and standard of care
Study NCT00098488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00098488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT02397733 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Prophylactic cranial irradiation (PCI)
Description: Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
Study NCT02397733 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance PCI
Description: Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
Study NCT04137211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with social break
Description: Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a short social break. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
Study NCT04137211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with walk break
Description: Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform a brisk walk for about three minutes on a treadmill at a predetermined speed and grade based on the fitness test performed during the familiarization session. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
Study NCT04137211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with simple resistance activities
Description: Participants are required to sit for three hours (reading is permitted), with a toilet break in between. Every thirty minutes participants will have a physical activity break, where they will perform simple resistance activities following a video for about three minutes. Test day begins at 7:30 with pretest measures, followed by the intervention at about 9:00, which will end around 12:00, with subsequent posttest measures.
Study NCT02227121 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defibrillation following induction of VT/VF
Description: Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
Study NCT02282436 — intervention group
Intervention type: OTHER
Intervention: No specific intervention for this study
Description: No specific intervention for this study
Study NCT02606565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intervention arm: 4% chlorhexidine
Description: See previous description
Study NCT03544138 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hummingbird Tympanostomy Tube System (H-TTS)
Description: The H-TTS is intended to deliver a tympanostomy tube through the tympanic membrane of a patient during a tympanostomy procedure.
Study NCT04365751 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Percutaneous microwave ablation, Laparoscopic hepatectomy
Description: For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
Study NCT04365751 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation, Laparoscopic hepatectomy
Description: For patients with hepatocellular carcinoma who meet the enrollment requirements, under the guidance of ultrasound, microwave ablation electrodes were implanted into the tumor tissues by percutaneous puncture, and the high-temperature heat energy was generated to cause coagulation necrosis of the tumor, so as to achieve the goal of local tumor treatment with minimally invasive technology.
Study NCT01056874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: Oral Digoxin 0.25 mg single dose
Study NCT01056874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral Digoxin 0.25 mg single dose on Day 5
Study NCT01056874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Oral Maraviroc 300 mg twice daily for 6 days
Study NCT00359086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: MGCD0103 given orally three times per week
Study NCT00414401 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical Reminder
Study NCT03970772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon Injection
Description: Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using mini-dose glucagon when their BG in range 40-69 mg/dl according a prescribed protocol.
Study NCT03970772 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Tablets
Description: Participants will be instructed to check their blood glucose (BG) with study meter once they developed hypoglycemia symptoms, their CGM reads below 70 mg/dl, or when the CGM glucose was trending down and the participant intended to treat to prevent hypoglycemia. Participants will be instructed to check BG with meter 3 times and treat the hypoglycemia event using glucose tablets when their BG in range 40-69 mg/dl according a prescribed protocol.
Study NCT02395003 — intervention group
Intervention type: OTHER
Intervention: Palmitate Diet
Description: Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
Study NCT04919421 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dental injection and topical gel application
Description: Topical anesthesia gel will be applied followed by dental injection with 1.8 ml Xylocaine 20mg/ml (DENSPLY Pharmaceutical); adrenaline: 1 : 100.000, delivered in cartridges using a 27 -gauge short needle (0.4 x 25 mm,C-K jet) and sterile non-aspirating syringe.
Study NCT04919421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental injection and virtual reality device
Description: Dental injection will be made while the participants are wearing virtual reality device.
Study NCT03494595 — intervention group
Intervention type: PROCEDURE
Intervention: Pediatric Liver transplantation
Description: Pediatric Liver transplantation
Study NCT01667783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Banding
Description: Laparoscopic Adjustable Gastric Banding using the LapBand
Study NCT01667783 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical Weight Loss
Description: Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
Study NCT01667783 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Bypass
Description: Laparoscopic Roux-en-Y Gastric Bypass
Study NCT06317246 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Investigation of BRAF mosaicism
Description: The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system
Study NCT00066131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal scaling and root planing
Description: Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
Study NCT00066131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
Study NCT03491449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.
Study NCT03491449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Maintaining a systolic blood pressure \<185mm Hg for 72 hours.
Study NCT02031848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention
Study NCT02031848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assessments and Diet Intake
Study NCT04596956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate Ringer injection
Description: Used in surgery
Study NCT04596956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's solution
Description: Used in surgery
Study NCT03501680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump.
Study NCT03501680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Group A: intensive insulin (glycemic control 4.4-6.1mmol/L), Group B: standard insulin (glycemic control 7.8-10.0 mmol/L), and Group C: plasmapheresis.~Insulin was injected by insulin pump.
Study NCT03501680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: plasmapheresis
Description: Triglyceridemia should be less than 5.65 mmol/l.
Study NCT02268669 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reperfusion strategies
Description: Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
Study NCT02992171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: care management by oncology nurses
Description: The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
Study NCT02565095 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stimulation of the carotid baroreceptors with a pressure system
Description: In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
Study NCT04291066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl cysteine
Description: Carbonyl scavenger and multi-vitamins with minerals to neutralize reactive carbonyl groups on the lipid aldehydes in patients with TBI
Study NCT01964664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Training
Description: 6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
Study NCT01964664 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Audio Group
Description: Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
Study NCT00996671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2256098
Description: focal adhesion kinase inhibitor given as a single dose
Study NCT00996671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to be used as comparator for GSK2256098
Study NCT03665909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote activity monitoring system
Description: The home-based sensor technology of eNeighbor relies on multiple, non-invasive and safe remote monitors (up to 6 sensors) that can alert family caregivers and/or health professionals to potentially negative situations that lead to adverse outcomes (e.g., wandering, falls, incomplete activity of daily living tasks). The technology platform of eNeighbor relies on wireless infrastructure that allows for remote monitoring via alerts that are communicated to the family caregiver's or nurse care manager's personal computers or handheld devices. The Alerts that are generated from the sensors detected abnormal motion or activity are sent to the family caregiver as well as a nurse care manager that monitors the real-time information generated by the eNeighbor sensors.
Study NCT02687048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Otago Exercise program
Description: The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
Study NCT02687048 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Otago Exercise program
Description: The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
Study NCT02687048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful meditation
Description: Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
Study NCT00265733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00265733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel poliglumex
Study NCT02457429 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Experiemental diagnostic procedure: Dx-pH measurement system
Description: The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.~The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours.
Study NCT02457429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peptest assay
Description: A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
Study NCT02457429 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: GORD symptom questionnaire
Description: A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
Study NCT01868841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AdreView
Description: 10 millicurie of AdreView (123I-mIBG)
Study NCT01868841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Study NCT04193566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Forxiga
Description: Forxiga®, dapagliflozin 10 mg film-coated tablet.~For further information please refer to:~https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.~Common side effects include hypoglycemia, hypotension, elevated hematocrite, dyslipidemia, back pain, dizziness, skin rash, urinary tract infection, vulvovaginitis and dehydration. Very rare incidents of ketoacidosis have been observed. Side effects have only been observed after use in longer periods and not in single-dose usage, as planned in the present study. A dose of 50 mg has been chosen to achieve optimal efficacy. Once-per-day doses of dapagliflozin for 12 weeks of 2.5 mg, 5 mg, 10 mg, 20 mg and 50 mg have been demonstrated to be relatively safe across the mentioned doses (20) and no apparent risk is expected from instituting two single-doses of 50 mg dapagliflozin.